Immuneering Corporation IMRX
3.71 USD -0.08 (-2.11%)
Nov 12, 2026, 1:16 PM EST
3.69 Day range 3.89
3.35 52-week range 8.48
- YTD
- -43.62%
- 1 year
- -43.96%
News
benzinga.com Immuneering Plans To Initiate Phase 2 Clinical Trial Evaluating Atebimetinib In Combination With Chemotherapy In Patients With Anaplastic Thyroid Cancer - Company plans to evaluate atebimetinib in combination with chemotherapy in a Phase 2 clinical trial in patients with anaplastic thyroid cancer (ATC), a highly aggressive cancer with significant…
benzinga.com Immuneering Enters Into Clinical Trial Collaboration And Supply Agreement To Supply Investigational MEK Inhibitor, Atebimetinib, For Two Astellas-Sponsored Studies Targeting Subset Of Pancreatic Cancer Patients - Collaboration aligns with Immuneering’s expanding strategy to provide a broad population of cancer patients with a wide set of treatment options -- Represents Immuneering’s fourth agreement with a…
globenewswire.com Immuneering Announces New Potentially Registrational Phase 2 Trial Evaluating Atebimetinib with Chemotherapy in Anaplastic Thyroid Cancer - Company plans to evaluate atebimetinib in combination with chemotherapy in a Phase 2 clinical trial in patients with anaplastic thyroid cancer (ATC), a highly aggressive cancer with significant…
globenewswire.com Immuneering to Collaborate with Astellas on Clinical Studies of Investigational CLDN18.2 Programs in Combination with Atebimetinib for Pancreatic Cancer Patients - Collaboration aligns with Immuneering's expanding strategy to provide a broad population of cancer patients with a wide set of treatment options - - Represents Immuneering's fourth agreement with a…
globenewswire.com Immuneering Appoints Accomplished Commercial Leader Grant Bogle to Board of Directors - Former TESARO Chief Commercial Officer and Nuvalent board member brings extensive experience in oncology product launches and commercial strategy - - Led commercialization of ZEJULA for ovarian…
benzinga.com Immuneering Announces Its Atebimetinib's Data Shows Improvement In Activity Of PD-1 Checkpoint Blockade In RAS-Mutant Colorectal And Lung Cancer Models; Demonstrates 50% Durable Complete Regression In Colorectal Model Immuneering Corporation (NASDAQ:IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today announced compelling preclinical data…
globenewswire.com Atebimetinib Combinations with Anti-PD1 Cured 50% of Mice in a RAS-Mutant Colorectal Cancer Model and Nearly Doubled Survival in a RAS-Mutant Lung Cancer Model; New Data Presented at SITC 2026 - Durable complete regressions observed in 50% of mice in a RAS-mutant colorectal cancer model treated with Atebimetinib plus anti-PD-1, with no regrowth even after dosing stopped - - Median survival…
benzinga.com Immuneering To Present Data At American Association For Cancer Research Conference On Pancreatic Cancer: New Frontiers In Biology And Therapeutic Development Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today announced it will present a poster at the…
benzinga.com Immuneering Highlights Atebimetinib’s Potential In 1L Metastatic Pancreatic Cancer As FDA Approves New 2L Treatment - For patients with second-line (2L) metastatic pancreatic cancer, today’s FDA approval of a new treatment is an important milestone – - For patients with first-line (1L) metastatic pancreatic…
benzinga.com This Lyell Immunopharma Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday Wall Street analysts change outlook on top names. Check analyst ratings page for all changes. See what analysts say about LYEL, IMRX, and RNA.- benzinga.com HC Wainwright & Co. Initiates Coverage On Immuneering with Buy Rating, Announces Price Target of $14 HC Wainwright & Co. analyst Andres Y. Maldonado initiates coverage on Immuneering (NASDAQ:IMRX) with a Buy rating and announces Price Target of $14.
benzinga.com Immuneering Q2 EPS $(0.27), Inline Immuneering (NASDAQ:IMRX) reported quarterly losses of $(0.27) per share which met the analyst consensus estimate. This is a 32.5 percent increase over losses of $(0.40) per share from the same…- benzinga.com Immuneering Publishes New Findings In Cancer Research Characterizing The Differentiated Mechanism And Broad Preclinical Activity Of Atebimetinib; Atebimetinib Showed Broad Antitumor Activity Across KRAS-, NRAS-, And BRAF-mutant Models, Including Colorectal, Lung, And Melanoma, By Resisting The RAF-Mediated Bypass Signaling That Has Constrained Other MEK Inhibitors - Atebimetinib showed broad antitumor activity across KRAS-, NRAS-, and BRAF-mutant models, including colorectal, lung, and melanoma, by resisting the RAF-mediated bypass signaling that has…
benzinga.com Needham Maintains Buy on Immuneering, Raises Price Target to $18 Needham analyst Ami Fadia maintains Immuneering (NASDAQ:IMRX) with a Buy and raises the price target from $11 to $18.- benzinga.com Immuneering Appoints Andrew Gengos CFO, Effective July 16 Immuneering Corporation (NASDAQ:IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today announced the appointment of Andrew Gengos as…
benzinga.com Immuneering Doses First Patient In MAPKeeper 301 Pivotal Phase 3 Clinical Study Of Atebimetinib Plus Modified Gemcitabine/Nab-Paclitaxel To Treat Metastatic Pancreatic Cancer Patients Immuneering Corporation (NASDAQ:IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today announced that the first patient has been dosed…
benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session - benzinga.com Immuneering Announces Updated Clinical Data From Ongoing Phase 2a Trial Evaluating Atebimetinib In Combination With mGnP In First-Line Metastatic Pancreatic Ductal Adenocarcinoma - 17.3 months median overall survival in 55 first-line pancreatic cancer patients; vs. 8.5 months for standard of care chemotherapy in the pivotal MPACT study -- Only two categories of Grade 3+…
benzinga.com Crude Oil Edges Higher; US Consumer Sentiment Falls In May US stocks rose, Dow gained over 400 points. S&P 500 and NASDAQ also up. Health care shares jumped, while communication services fell. University of Michigan's consumer sentiment index hit record low.…
benzinga.com Zoom Upbeat Q1 Results, Joins Lionsgate Studios, Ross Stores And Other Big Stocks Moving Higher On Friday Zoom Communications Inc shares rise after strong financial results and increased buyback authorization. Other big gainers include IMRX, INFQ, ASMB, IMAX, RGTI, HLIT, DELL, EL, GSIT, ELVR, and HPQ.- benzinga.com Immuneering Reveals 17.3 Months Median Overall Survival in First-Line Metastatic Pancreatic Cancer Patients Treated with Atebimetinib Plus Chemotherapy; Tolerability Profile Consistent With Prior Updates; Only Two Categories Of Grade 3 Or Higher Treatment-Related Adverse Events Observed In ≥10% Of Patients, Both Chemotherapy-Related Immuneering Corporation (NASDAQ:IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today reported a 17.3-month median overall survival…
- benzinga.com Immuneering Q1 EPS $(0.21) Beats $(0.26) Estimate Immuneering (NASDAQ:IMRX) reported quarterly losses of $(0.21) per share which beat the analyst consensus estimate of $(0.26) by 19.23 percent. This is a 50 percent increase over losses of $(0.42)…
benzinga.com Immuneering To Present Updated Data From Phase 2a Clinical Trial Evaluating Atebimetinib In Combination With mGnP In First-Line Pancreatic Cancer At 2026 ASCO Annual Meeting - New data from Phase 2a clinical trial evaluating atebimetinib + mGnP in first-line pancreatic cancer will be presented in an oral session by Dr. Peter Vu, UC San Diego Health -- The ASCO…- benzinga.com Immuneering To Present Atebimetinib ctDNA Data Showing Durable Tumor Shrinkage At AACR 2026 Immuneering Corporation (NASDAQ:IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today announced it will present a poster on one of the…
- benzinga.com Immuneering Q4 EPS $(0.18) Beats $(0.31) Estimate Immuneering (NASDAQ:IMRX) reported quarterly losses of $(0.18) per share which beat the analyst consensus estimate of $(0.31) by 42.31 percent. This is a 68.97 percent increase over losses of $(0.58)…
benzinga.com Looking Into Immuneering Corp's Recent Short Interest 
benzinga.com Benzinga Bulls And Bears: Chevron, Palantir, Aquestive — And Real Estate Stocks Plummet Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories.
benzinga.com Dow Jumps Over 250 Points; US Initial Jobless Claims Increase - benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session
benzinga.com Nasdaq Falls Over 100 Points; Acuity Posts Upbeat Earnings 
benzinga.com Immuneering Pancreatic Cancer Trial Touts Encouraging Survival Data, But Stock Moves Lower Immuneering shares traded lower after new pancreatic cancer trial data showed improved survival, manageable safety, and key trial milestones expected in 2026.
benzinga.com Stock Market Today: S&P 500, Dow Jones, Nasdaq 100 Futures Drop— AZZ, Northrop Grumman, Immuneering In Focus (UPDATED) (Editor’s note: The future prices of benchmark tracking ETFs and the headline were updated in the story.) U.S. stock futures declined on Thursday following a mixed close on Tuesday, with only the…
benzinga.com Immuneering, Phathom Pharmaceuticals, Canadian Solar And Other Big Stocks Moving Lower In Thursday's Pre-Market Session 
benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session 
benzinga.com Why AZZ Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket 
benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session - benzinga.com Immuneering Reports Updated Overall Survival And Safety Data From Its Ongoing Phase 2a Trial Of Atebimetinib In Combination With Modified Gemcitabine/Nab-Paclitaxel In First-line Pancreatic Cancer Patients With Over 13 Months Median Follow Up Time; Atebimetinib Consistently Demonstrates Overall Survival Advantage At All Time Periods Reported; Median Overall Survival Remains Unreached As Of Data Cutoff Immuneering Corporation (NASDAQ:IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today announced positive updated overall survival (OS)…
benzinga.com Monte Rosa Therapeutics, Ventyx Biosciences, United Microelectronics And Other Big Stocks Moving Higher On Wednesday 
benzinga.com Dynavax Technologies, Omeros, Agios Pharmaceuticals, Nike And Other Big Stocks Moving Higher On Wednesday - benzinga.com Immuneering To Provide 12-Month Overall Survival From Its Current Phase 2a Clinical Study Of Atebimetinib + Modified Gemcitabine In Pancreatic Participants Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today announced that it will host a conference call…
- benzinga.com Immuneering On Track To First Patient Dosing For Phase 3 Atebimetinib Trial For First-Line Metastatic Pancreatic Cancer Patients; Completed End-Of-Phase 2 Interaction With FDA And Received Scientific Advice From EMA – End-of-Phase 2 interactions with FDA complete; scientific advice received from EMA –– Company expects to dose first patient in global Phase 3 registrational trial, MAPKeeper 301, in mid-2026 ––…
- benzinga.com Immuneering To Be Added To Nasdaq Biotechnology Index, Effective December 22 Immuneering Corporation (NASDAQ:IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today announced that it is expected to be added to the…
- benzinga.com Chardan Capital Maintains Buy on Immuneering, Maintains $20 Price Target Chardan Capital analyst Geulah Livshits maintains Immuneering (NASDAQ:IMRX) with a Buy and maintains $20 price target.
- benzinga.com Immuneering Q3 EPS $(0.38) Beats $(0.39) Estimate Immuneering (NASDAQ:IMRX) reported quarterly losses of $(0.38) per share which beat the analyst consensus estimate of $(0.39) by 3.06 percent. This is a 22.45 percent increase over losses of $(0.49)…
benzinga.com Earnings Scheduled For November 12, 2025 
benzinga.com This Immuneering Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday - benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session Gainers PepGen (NASDAQ: PEPG) shares rose 141.0% to $6.41 during Thursday's pre-market session. The market value of their outstanding shares is at $87.2 million.
benzinga.com Why PepGen Shares Are Trading Higher By 112%; Here Are 20 Stocks Moving Premarket Shares of PepGen Inc. (NASDAQ: PEPG) rose sharply in pre-market trading after the company announced the launch of an underwritten public offering of common stock and pre-funded warrants.- benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session